205 related articles for article (PubMed ID: 33955686)
1. Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies.
Desrivot J; Van Kaem T; Allamassey L; Helmer E
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1007-1017. PubMed ID: 33955686
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
Zahir H; Kobayashi F; Zamora C; Gajee R; Gordon MS; Babiker HM; Wang Q; Greenberg J; Wagner AJ
J Clin Pharmacol; 2021 Mar; 61(3):298-306. PubMed ID: 32918831
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
6. GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects.
Timmis H; Van Kaem T; Desrivot J; Dupont S; Meuleners L; Beetens J; Helmer E; Santermans E; Huettner S
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):994-1006. PubMed ID: 33960725
[TBL] [Abstract][Full Text] [Related]
7. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
8. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.
Kvitne KE; Åsberg A; Johnson LK; Wegler C; Hertel JK; Artursson P; Karlsson C; Andersson S; Sandbu R; Skovlund E; Christensen H; Jansson-Löfmark R; Hjelmesaeth J; Robertsen I
Clin Transl Sci; 2022 Nov; 15(11):2685-2696. PubMed ID: 36037309
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
10. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
Murase K; Lee L; Ma J; Barrett R; Thoolen M
Eur J Clin Pharmacol; 2022 Nov; 78(11):1823-1831. PubMed ID: 36166059
[TBL] [Abstract][Full Text] [Related]
12. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
[TBL] [Abstract][Full Text] [Related]
13. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.
Stage TB; Graff M; Wong S; Rasmussen LL; Nielsen F; Pottegård A; Brøsen K; Kroetz DL; Khojasteh SC; Damkier P
Br J Clin Pharmacol; 2018 Mar; 84(3):510-519. PubMed ID: 29105855
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity.
Kvitne KE; Krogstad V; Wegler C; Johnson LK; Kringen MK; Hovd MH; Hertel JK; Heijer M; Sandbu R; Skovlund E; Artursson P; Karlsson C; Andersson S; Andersson TB; Hjelmesaeth J; Åsberg A; Jansson-Löfmark R; Christensen H; Robertsen I
Br J Clin Pharmacol; 2022 Sep; 88(9):4121-4133. PubMed ID: 35404513
[TBL] [Abstract][Full Text] [Related]
16. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
[TBL] [Abstract][Full Text] [Related]
17. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
18. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.
Ma JD; Nafziger AN; Villano SA; Gaedigk A; Bertino JS
Antimicrob Agents Chemother; 2006 Apr; 50(4):1130-5. PubMed ID: 16569820
[TBL] [Abstract][Full Text] [Related]
19. African Lettuce (Launaea taraxacifolia) Displays Possible Anticancer Effects and Herb-Drug Interaction Potential by CYP1A2, CYP2C9, and CYP2C19 Inhibition.
Thomford NE; Mkhize B; Dzobo K; Mpye K; Rowe A; Parker MI; Wonkam A; Skelton M; September AV; Dandara C
OMICS; 2016 Sep; 20(9):528-37. PubMed ID: 27631192
[TBL] [Abstract][Full Text] [Related]
20. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
